Interatrial Shunt Devices Market – By Product Type, By Application, By End Use – Global Forecast, 2025 - 2034

Interatrial Shunt Devices Market Size

The interatrial shunt devices market size was valued at around USD 3.8 billion in 2024 and is estimated to grow at 7% CAGR from 2025 - 2034. An interatrial shunt device is a type of medical device built to create a controlled dynamic passage (or shunt) between the left and right atrium of the heart. The shunt enables blood circulation between the two atria normally to decrease pressure differential or enhance heart functioning in targeted medical conditions. Usually, these devices are used to manage some types of heart failure and pulmonary hypertension patients.
 

The interatrial shunt devices market is primarily driven by the increasing prevalence of heart failures across the globe. For instance, according to the Journal of Cardiac Failure, nearly 6.7 million Americans aged over 20 years suffer from heart failure, and the number is further estimated to reach 8.5 million by the year 2030. With the increase in the global population and age, and the high comorbid lifestyle-related risk factors, the incidence of heart failure continues to grow.
 

Interatrial shunt devices are new options that offer heart failure patients a less invasive means of treatment, particularly for patients with preserved ejection fraction (HFpEF). These devices are also an alternative to traditional pharmacologic therapies that have limited usefulness in some patient populations.
 

Additionally, rapid innovations in interatrial shunt devices are bolstering the growth of the market. Newer device configurations, novel materials, and changes to implantation practices are improving the safety and effectiveness of these treatments. At the same time, the growing number of clinical studies substantiating interatrial shunt device use is elevating physician confidence levels and use rates. The market is likely to grow for these devices as more long-term data is amassed, regulatory clearances are issued in additional regions, and investment activities increase in the future.
 

Interatrial Shunt Devices Market Trends

• The market is experiencing an increase in clinical trials and other research activities. Many firms are testing these devices for their safety and performance, especially for heart failure patients. This may lead to the creation of a strong clinical platform and increase the acceptance of interatrial shunt devices in practice.
   
• Focus on less invasive, smaller-sized interatrial shunt devices is increasing among manufacturers. The goal of this trend is to decrease the severity of procedures, enhance patient satisfaction, and increase chances of a successful outcome. The use of smaller devices may also increase the number of treated patients, which is good for the market.
   
• The interatrial shunt devices are gradually shifting into the utilization of advanced materials within the devices, which comes with a plethora of advantages. Complications can be minimized, and long-term outcomes can be improved with the aid of enhanced biocompatible materials as well. These improvements are believed to inch the interatrial shunt devices technology to another level.
   
• With the aim of getting regulatory permission in different regions, many new parts of the globe are being explored for the interatrial shunt devices. As interatrial shunt devices become prevalent, there is an opportunity for economic growth in regions where heart failure is becoming a common affliction. These regions are expected to make a considerable impact on the global economy as the barriers of regulations are beaten and marketing awareness expands.
   
• From monitoring systems to interatrial shunt devices, all of these products are now becoming optimized for user-centric design and plans. With the aim of improving patient satisfaction, many device manufacturers now consider the anatomy of the patient and the heart failure condition for which the device is being made. This level of customization is bound to show great improvement in treatment results.
   
•  A notable trend is the adoption of telemetry within post-operative patient care. Interatrial shunt devices with remote monitoring capabilities are being built, which makes it possible for physicians to evaluate the patients and the devices without seeing the patients in the office as frequently. This trend is likely to enhance patient care and lower costs for the healthcare system.
   
• Other noteworthy advances are the application of artificial intelligence (AI) technology with interatrial shunt devices. Algorithms are being developed to help select patients, manage settings of the device, and anticipate potential complications. It is anticipated that this synergy of technology and medical devices will improve the overall effectiveness of treatment and outcomes in patients with interatrial shunt devices.
   

Interatrial Shunt Devices Market Analysis

Based on product type, the market is segmented into balloon expandable devices, self-expanding devices, and other product types. The balloon expandable devices dominated the market with the largest revenue of USD 2.1 billion in 2024 and is expected to grow at a significant CAGR over the forecast period.
 

• Balloon expandable interatrial shunt devices have recently been gaining traction in the market due to a diverse range of benefits during deployment and positioning. Their use results in improved placement accuracy and controlled expansion, which allows the physician to modify the size of the shunt during surgery. Additionally, this flexibility permits shunt size optimization specific to each patient's anatomy, which can potentially reduce complications and improve clinical outcomes.
   
• Additionally, the balloon expandable mechanism also enhances device stability after deployment, which alleviates the risk of device movement. This feature is particularly important for the shunt whose long-term effectiveness is vital. In addition, the balloon expandable design has a more compact delivery profile than other self-expanding designs, which may aid with ease of implantation and increase the number of people who can receive treatment.
   
• Furthermore, balloon expandable devices tend to possess greater radial strength, which may help in keeping the shunt patent for longer. This attribute, together with the mechanism of attaining controlled final diameter, explains why there is increasing preference of interventional cardiologists towards the balloon expandable interatrial shunt devices. This increase in preference is contributing to market growth.
   

Based on application, the interatrial shunt devices market is segmented into heart failure management, pulmonary hypertension treatment and other applications. The heart failure management segment of the market, which held a 68.9% share in 2024, is poised for substantial growth in the coming years.
 

• The excessive application of interatrial shunt devices in managing heart failure is because there is a shift from traditional medical therapy towards device-based therapy, where patients with heart failure with preserved ejection fraction (HFpEF) benefit the most from them. The shunt enhancers significantly lower the left atrial pressure, which is the principal cause of symptoms in these patients. These patients show improvements in their symptoms with little to no existing medication. Pharmacological management of this population is usually poor, making these devices highly desirable. The increase in the older population suffering from HFpEF has made the situation dire and there is an increased need to tackle this issue with innovative methods.
   
• There has been a change in interatrial shunt devices technology, and this has led to an increase in their usage in heart failure management. Modernized device and implantation techniques have resulted in better final patient outcomes, as well as decreased complications associated with procedures. This has led to greater trust among physicians to recommend and employ these devices, which has further strengthened their grip as a primary treatment method in the global heart failure management market.

Based on end use, the interatrial shunt devices market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and other end users. The hospitals segment of the market, which held a 54.8% share in 2024, is poised for substantial growth in the coming years.
 

• The general population demographic trends showing an increase in heart failure and elderly people are major reasons for the increased numbers of interatrial shunt devices used in hospitals. For example, based on the data published by WHO, the global population of older people (more than 60 years of age) is projected to rise from 12 percent of the total population in 2015 to 22 percent by 2050.
   
• To deal with these more advanced cases, hospitals are now introducing more interventional options like interatrial shunt devices to more advanced treatment for complex cardiac cases. More and more hospitals are adopting these devices for the management of heart failure because they can lower the left atrial pressure and improve symptoms.

The U.S. dominated the North American interatrial shunt devices market with revenue of USD 1.1 billion in 2024 and is projected to witness substantial growth over the forecast period.
 

• Due to the high prevalence of cardiovascular diseases and advanced healthcare infrastructure, the United States comes first in the interatrial shunt device market. For instance, according to CDC data, around 702,880 people died due to heart disease in 2022 in the U.S.
   
• Additionally, U.S. innovative interatrial shunt devices are a result of the country’s robust research and development capabilities along with other medical technological investments.
   
• This contributes to the high rate at which these devices are adopted into U.S. hospitals due to the level of innovation achieved in the country.
   

The interatrial shunt devices market in the UK is expected to experience significant growth from 2025 to 2034.
 

• The rising demand for interatrial shunt devices in the UK can be attributed to the healthcare system pushing for better patient results and normal invasive procedures.
   
• Additionally, according to the British Heart Foundation, over 7.6 million people in the UK have heart and circulatory diseases, makes us conclude that there is an increased rate of cardiovascular problems and there are favorable reimbursement policies for cardiovascular procedures.
   
• In the UK, the expanding elderly population, in addition to the increase in awareness about heart failure treatments, is also contributing to the increased use of these devices.
   

The Asia Pacific interatrial shunt devices market is anticipated to witness lucrative growth between 2025 and 2034.
 

• The Asia Pacific market is expected to grow due to increasing patient numbers suffering from heart failure and other cardiovascular diseases in the region. For example, in China, as noted in the Biomedical and Environmental Sciences journal, about 330 million people were afflicted with cardiovascular disease and 8.9 million had heart failure.
   
• Lifestyle-associated risk factors become more commonplace as people grow older and the use of interatrial shunt devices, among other treatments, is expected to increase.
   
• Furthermore, the increasing awareness of healthcare providers and patients regarding the advantages of minimally invasive techniques to manage heart failure further facilitates the growth of the market.
   

The interatrial shunt devices market in Saudi Arabia is expected to experience significant growth from 2025 to 2034.
 

• The increasing usage of interatrial shunt devices for treatment is attributable to a rise in countries using such devices as the rate of cardiovascular diseases such as congenital heart disease continues to grow. There is also an increasing awareness of the need for these interventions, and the improvements in diagnostic imaging and other investigations mean that more and more interatrial shunts will be needed.
   
• Additionally, the dedication of the Saudi government to improving the health sector is correlated with increased provision of therapies involving interatrial shunt devices. These factors consequently lead to the expansion of the entire market.
   

Interatrial Shunt Devices Market Share

The market is characterized by intense competition among key players such as Corvia Medical, Johnson & Johnson, and Occlutech. All these companies are placing a strong emphasis on new product integrations and joint ventures for competitive advantage. Widening heart failure disease burden and the minimally invasive treatment option market are two of the central reasons for market growth for such devices. Companies heavily spend on clinical trials of their devices in order to prove device efficacy and safety. This serves as a hurdle to market entry but creates a competitive advantage post-entry.
 

Additionally, market participants employ regional expansion and distribution agreements as a means of capturing a larger share of the international market. New entrants are also emerging with competitive technologies, increasing rivalry in the existing space. There is a race to claim the first-mover advantage in the spatial market as it is still in the nascent phase. The race involves new entrants acquiring the prescribed imaging technologies, new patents, and alliances with existing medical and research institutions.
 

Interatrial Shunt Devices Market Companies

Some of the eminent market participants operating in the interatrial shunt devices industry include:

• Adona Medical
• Alleviant Medical
• BioVentrix
• Corvia Medical
• CryoLife
• Edwards Lifesciences
• Gore Medical
• InterShunt Technologies
• Johnson & Johnson
• Lepu Medical
• Medtronic
• Micro Interventional Devices
• Occlutech
• Venus Medtech
• Wuhan Weike Medical Technology
   

USPs for key players:

• Occlutech's Atrial Flow Regulator (AFR) enables controlled interatrial flow. The device aims to improve clinical outcomes while reducing procedural risks for heart failure patients.
   
• Venus Medtech develops structural heart disease solutions, including interatrial shunt devices. The company's devices feature coating technologies that enhance biocompatibility and durability for patient safety and effectiveness.
   
• Medtronic combines interatrial shunt solutions with imaging and navigation technologies, building on its experience in minimally invasive cardiac devices. This integration helps achieve accurate device placement and improved treatment outcomes.
   
• BioVentrix develops left-ventricular remodeling technologies that work alongside interatrial shunt devices. The company's approach addresses heart failure through multiple treatment methods for cardiac patients.
   

Interatrial Shunt Devices Industry News:

• In October 2024, Johnson & Johnson acquired V-Wave, a company focused on developing new and unique treatments for heart failure patients. The acquisition of V-Wave broadened Johnson & Johnson’s cardiology solutions as well as widened their customer base.
   

The interatrial shunt devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Balloon expandable devices
• Self-expanding devices
• Other product types

Market, By Application

• Heart failure management
• Pulmonary hypertension treatment
• Other applications

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Specialty clinics
• Other end users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America 
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE